U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drucker A, Adam GP, Langberg V, et al. Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Dec. (Comparative Effectiveness Reviews, No. 199.)

Cover of Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin

Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin [Internet].

Show details

References

1.
Centers for Disease Control and Prevention Skin Cancer Statistics. 2015. http://www​.cdc.gov/cancer​/skin/statistics/index.htm.
2.
Rogers HW, Weinstock MA, Feldman SR, et al. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatol. 2015 Oct 1;151(10):1081–6. doi: 10.1001/jamadermatol.2015.1187. PMID: 25928283. [PubMed: 25928283] [CrossRef]
3.
Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006 Sep;55(3):490–500. doi: 10.1016/j.jaad.2006.05.048. PMID: 16908356. [PubMed: 16908356] [CrossRef]
4.
Karimkhani C, Dellavalle RP, Coffeng LE, et al. Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013. JAMA Dermatol. 2017 Mar 01doi: 10.1001/jamadermatol.2016.5538. PMID: 28249066. [PMC free article: PMC5817488] [PubMed: 28249066] [CrossRef]
5.
Wu W, Weinstock MA. Trends of keratinocyte carcinoma mortality rates in the United States as reported on death certificates, 1999 through 2010. Dermatol Surg. 2014 Dec;40(12):1395–401. doi: 10.1097/DSS.0000000000000194. PMID: 25393350. [PubMed: 25393350] [CrossRef]
6.
Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013 Jun;68(6):957–66. doi: 10.1016/j.jaad.2012.11.037. PMID: 23375456. [PubMed: 23375456] [CrossRef]
7.
Oh CC, Hofbauer GF, Serra AL. et al. Painful skin lesions and squamous cell carcinoma predict overall mortality risk in organ transplant recipients: A cohort study. Br J Dermatol. 2016 Dec 23doi: 10.1111/bjd.15269. PMID: 28012178. [PubMed: 28012178] [CrossRef]
8.
U. S. Department of Health and Human Services. Reports of the Surgeon General. The Surgeon General’s Call to Action to Prevent Skin Cancer. Washington (DC): Office of the Surgeon General (US); 2014. [PubMed: 25320835]
9.
Cakir BO, Adamson P, Cingi C. Epidemiology and economic burden of nonmelanoma skin cancer. Facial Plast Surg Clin North Am. 2012 Nov;20(4):419–22. doi: 10.1016/j.fsc.2012.07.004. PMID: 23084294. [PubMed: 23084294] [CrossRef]
10.
Casey S, Best L, Vujovic O, et al. Use of Protoporphyrin Fluorescence to Determine Clinical Target Volume for Non-melanotic Skin Cancers Treated with Primary Radiotherapy. Cureus. 2016 Sep 04;8(9):e767. doi: 10.7759/cureus.767. PMID: 27725923. [PMC free article: PMC5050029] [PubMed: 27725923] [CrossRef]
11.
Lucena SR, Salazar N, Gracia-Cazana T, et al. Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer. Int J Mol Sci. 2015 Oct 28;16(10):25912–33. doi: 10.3390/ijms161025912. PMID: 26516853. [PMC free article: PMC4632833] [PubMed: 26516853] [CrossRef]
12.
Yoon J, Phibbs CS, Chow A, et al. Costs of Keratinocyte Carcinoma (Nonmelanoma Skin Cancer) and Actinic Keratosis Treatment in the Veterans Health Administration. Dermatol Surg. 2016 Sep;42(9):1041–7. doi: 10.1097/dss.0000000000000820. PMID: 27465252. [PubMed: 27465252] [CrossRef]
13.
Linos E, Chren MM, Stijacic Cenzer I, et al. Skin Cancer in U.S. . Elderly Adults: Does Life Expectancy Play a Role in Treatment Decisions? J Am Geriatr Soc. 2016 Aug;64(8):1610–5. doi: 10.1111/jgs.14202. PMID: 27303932. [PMC free article: PMC5459407] [PubMed: 27303932] [CrossRef]
14.
Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007 Aug;4(8):462–9. doi: 10.1038/ncponc0883. PMID: 17657251. [PubMed: 17657251] [CrossRef]
15.
Jacobsen AA, Aldahan AS, Hughes OB, et al. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies. JAMA Dermatol. 2016 Apr 20doi: 10.1001/jamadermatol.2016.0780. PMID: 27096888. [PubMed: 27096888] [CrossRef]
16.
Jung JY, Linos E. Adding active surveillance as a treatment option for low risk skin cancers in patients with limited life expectancy. J Geriatr Oncol. 2016 May;7(3):221–2. doi: 10.1016/j.jgo.2016.03.008. PMID: 27133284. [PubMed: 27133284] [CrossRef]
17.
Linos E, Parvataneni R, Stuart SE, et al. Treatment of nonfatal conditions at the end of life: nonmelanoma skin cancer. JAMA Intern Med. 2013 Jun 10;173(11):1006–12. doi: 10.1001/jamainternmed.2013.639. PMID: 23699934. [PMC free article: PMC3726204] [PubMed: 23699934] [CrossRef]
18.
Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):96–105. doi: 10.1016/S1470-2045(13)70530-8. PMID: 24332516. [PubMed: 24332516] [CrossRef]
19.
Kuijpers DI, Thissen MR, Berretty PJ, et al. Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg. 2007 May;33(5):579–87. doi: 10.1111/j.1524-4725.2007.33117.x. PMID: 17451581. [PubMed: 17451581] [CrossRef]
20.
Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol. 2008 Sep;159(4):864–70. doi: 10.1111/j.1365-2133.2008.08787.x. PMID: 18717680. [PubMed: 18717680] [CrossRef]
21.
Ozolins M, Williams HC, Armstrong SJ, et al. The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials. 2010;11:42. doi: 10.1186/1745-6215-11-42. PMID: 20409337. [PMC free article: PMC2877028] [PubMed: 20409337] [CrossRef]
22.
Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007 Sep;143(9):1131–6. doi: 10.1001/archderm.143.9.1131. PMID: 17875873. [PubMed: 17875873] [CrossRef]
23.
Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med. 2008 Feb;40(2):153–8. doi: 10.1002/lsm.20606. PMID: 18306163. [PubMed: 18306163] [CrossRef]
24.
Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2007(1):CD003412. doi: 10.1002/14651858.CD003412.pub2. PMID: 17253489. [PubMed: 17253489] [CrossRef]
25.
Clark CM, Furniss M, Mackay-Wiggan JM. Basal cell carcinoma: an evidence-based treatment update. Am J Clin Dermatol. 2014 Jul;15(3):197–216. doi: 10.1007/s40257-014-0070-z. PMID: 24733429. [PubMed: 24733429] [CrossRef]
26.
Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153. doi: 10.1136/bmj.f6153. PMID: 24191270. [PMC free article: PMC3816607] [PubMed: 24191270] [CrossRef]
27.
Lansbury L, Leonardi-Bee J, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin. Cochrane Database Syst Rev. 2010(4):CD007869. doi: 10.1002/14651858.CD007869.pub2. PMID: 20393962. [PubMed: 20393962] [CrossRef]
28.
Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009 Dec;145(12):1431–8. doi: 10.1001/archdermatol.2009.291. PMID: 20026854. [PubMed: 20026854] [CrossRef]
29.
Mosterd K, Arits AH, Thissen MR, et al. Histology-based treatment of basal cell carcinoma. Acta Derm Venereol. 2009;89(5):454–8. doi: 10.2340/00015555-0710. PMID: 19734968. [PubMed: 19734968] [CrossRef]
30.
Roozeboom MH, Arits AH, Nelemans PJ, et al. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol. 2012 Oct;167(4):733–56. doi: 10.1111/j.1365-2133.2012.11061.x. PMID: 22612571. [PubMed: 22612571] [CrossRef]
31.
Thissen MR, Neumann MH, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999 Oct;135(10):1177–83. PMID: 10522664. [PubMed: 10522664]
32.
Basal Cell Carcinoma, Squamous Cell Carcinoma, and Related Lesions: A Guide to Clinical Management in Australia. Cancer Council Australia and Australian Cancer Network. 2008.
33.
Finnish Medical Society Duodecim. Naevi and skin cancer (basal cell and epidermoid carcinoma). In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2010.
34.
US Department of Health Human Services. The surgeon general’s call to action to prevent skin cancer. 2014. [PubMed: 25320835]
35.
Mudigonda T, Pearce DJ, Yentzer BA, et al. The economic impact of non-melanoma skin cancer: a review. J Natl Compr Canc Netw. 2010 Aug;8(8):888–96. PMID: 20870635. [PubMed: 20870635]
36.
Linos E, VanBeek M, Resneck JS, Jr. A Sudden and Concerning Increase in the Use of Electronic Brachytherapy for Skin Cancer. JAMA Dermatol. 2015 Jul;151(7):699–700. doi: 10.1001/jamadermatol.2015.0385. PMID: 25785818. [PubMed: 25785818] [CrossRef]
37.
AHRQ Methods for Effective Health Care. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.
38.
Halladay CW, Trikalinos TA, Schmid IT, et al. Using data sources beyond PubMed has a modest impact on the results of systematic reviews of therapeutic interventions. J Clin Epidemiol. 2015 Sep;68(9):1076–84. doi: 10.1016/j.jclinepi.2014.12.017. PMID: 26279401. [PubMed: 26279401] [CrossRef]
39.
Deploying an interactive machine learning system in an evidence-based practice center: abstrackr. Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium; 2012. ACM.
40.
Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928. doi: 10.1136/bmj.d5928. PMID: 22008217. [PMC free article: PMC3196245] [PubMed: 22008217] [CrossRef]
41.
Wells GAS, B.;O’Connell, D.;Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www​.ohri.ca/programs​/clinical_epidemiology/oxford.asp.
42.
Carija A, Puizina-Ivic N, Vukovic D, et al. Single treatment of low-risk basal cell carcinomas with pulsed dye laser-mediated photodynamic therapy (PDL-PDT) compared with photodynamic therapy (PDT): A controlled, investigator-blinded, intra-individual prospective study. Photodiagnosis Photodyn Ther. 2016 Dec;16:60–5. doi: 10.1016/j.pdpdt.2016.08.003. PMID: 27516420. [PubMed: 27516420] [CrossRef]
43.
Choi SH, Kim KH, Song KH. Effect of Methyl Aminolevulinate Photodynamic Therapy With and Without Ablative Fractional Laser Treatment in Patients With Microinvasive Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA Dermatol. 2017 Feb 15doi: 10.1001/jamadermatol.2016.4463. PMID: 28199463. [PubMed: 28199463] [CrossRef]
44.
Dummer R, Migden M, Guminski A, et al. Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: Results of the BOLT 30-month analysis. Melanoma Research. 2016;26:e3. doi: 10.1097/CMR.0000000000000285. [CrossRef]
45.
Abbade L, Gige T, Amaral V, et al. Higher recurrence rates of head and neck nodular basal cell carcinoma treated with topical photodynamic therapy (MAL-PDT) compared to surgical excision: A randomized controlled study. Journal of the American Academy of Dermatology; 2015. p. Ab185.
46.
Al-Niaimi F, Sheth N, Kurwa HA, et al. Photodynamic Therapy Followed by Mohs Micrographic Surgery Compared to Mohs Micrographic Surgery Alone for the Treatment of Basal Cell Carcinoma: Results of a Pilot Single-Blinded Randomised Controlled Trial. J Cutan Aesthet Surg. 2015 Apr–Jun;8(2):88–91. doi: 10.4103/0974-2077.158443. PMID: 26157307. [PMC free article: PMC4477468] [PubMed: 26157307] [CrossRef]
47.
Allen ED, McGill JI, Hall VL, et al. Cryotherapy of basal cell lesions. Trans Ophthalmol Soc U K. 1979 Jul;99(2):264–8. PMID: 298425. [PubMed: 298425]
48.
Alpsoy E, Yilmaz E, Basaran E, et al. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma. J Dermatol. 1996 Jun;23(6):394–6. PMID: 8708151. [PubMed: 8708151]
49.
Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013 Jun;14(7):647–54. doi: 10.1016/s1470-2045(13)70143-8. PMID: 23683751. [PubMed: 23683751] [CrossRef]
50.
Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer. 1997;76(1):100–6. PMID: 9218740. [PMC free article: PMC2223779] [PubMed: 9218740]
51.
Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008 Sep–Oct;18(5):547–53. doi: 10.1684/ejd.2008.0472. PMID: 18693158. [PubMed: 18693158] [CrossRef]
52.
Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):96–105. doi: 10.1016/s1470-2045(13)70530-8. PMID: 24332516. [PubMed: 24332516] [CrossRef]
53.
Berroeta L, Clark C, Dawe RS, et al. A randomized study of minimal curettage followed by topical photodynamic therapy compared with surgical excision for low-risk nodular basal cell carcinoma. Br J Dermatol. 2007 Aug;157(2):401–3. doi: 10.1111/j.1365-2133.2007.07996.x. PMID: 17573890. [PubMed: 17573890] [CrossRef]
54.
Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999 Dec;41(6):1002–7. PMID: 10570388. [PubMed: 10570388]
55.
Brinkhuizen T, Frencken KJ, Nelemans PJ, et al. The effect of topical diclofenac 3% and calcitriol 3 mug/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial. J Am Acad Dermatol. 2016 Jul;75(1):126–34. doi: 10.1016/j.jaad.2016.01.050. PMID: 27067393. [PubMed: 27067393] [CrossRef]
56.
Butler DF, Parekh PK, Lenis A. Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. Dermatol Surg. 2009 Jan;35(1):24–9. doi: 10.1111/j.1524-4725.2008.34378.x. PMID: 19018814. [PubMed: 19018814] [CrossRef]
57.
Cai H, Wang YX, Zheng JC, et al. Photodynamic therapy in combination with CO2 laser for the treatment of Bowen’s disease. Lasers Med Sci. 2015 Jul;30(5):1505–10. doi: 10.1007/s10103-015-1754-1. PMID: 25899562. [PubMed: 25899562] [CrossRef]
58.
Choi SH, Kim KH, Song KH. Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. J Eur Acad Dermatol Venereol. 2016 May;30(5):783–8. doi: 10.1111/jdv.13453. PMID: 26551044. [PubMed: 26551044] [CrossRef]
59.
Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694–700. PMID: 2229497. [PubMed: 2229497]
60.
Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul;75(1):113–25.e5. doi: 10.1016/j.jaad.2016.02.1226. PMID: 27067394. [PubMed: 27067394] [CrossRef]
61.
Edwards L, Tucker SB, Perednia D, et al. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas. Arch Dermatol. 1990 Aug;126(8):1029–32. PMID: 2383027. [PubMed: 2383027]
62.
Edwards L, Whiting D, Rogers D, et al. The effect of intralesional interferon gamma on basal cell carcinomas. J Am Acad Dermatol. 1990 Mar;22(3):496–500. PMID: 2107219. [PubMed: 2107219]
63.
Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007 Oct;57(4):616–21. doi: 10.1016/j.jaad.2007.05.022. PMID: 17610993. [PubMed: 17610993] [CrossRef]
64.
Eimpunth S, Oganesyan G, Hamman MS, et al. Effectiveness of a 595-nm pulsed dye laser for the treatment of basal cell carcinoma using 1 stacked-pulse session. Journal of the American Academy of Dermatology; 2014. p. Ab134.
65.
Essers BA, Dirksen CD, Nieman FH, et al. Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol. 2006 Feb;142(2):187–94. doi: 10.1001/archderm.142.2.187. PMID: 16490846. [PubMed: 16490846] [CrossRef]
66.
Foley P, Freeman M, Menter A, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol. 2009 Nov;48(11):1236–45. doi: 10.1111/j.1365-4632.2008.04022.x. PMID: 20064185. [PubMed: 20064185] [CrossRef]
67.
Garcia-Martin E, Gil-Arribas LM, Idoipe M, et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. Br J Ophthalmol. 2011 Oct;95(10):1393–6. doi: 10.1136/bjo.2010.193078. PMID: 21242584. [PubMed: 21242584] [CrossRef]
68.
Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004 May;50(5):722–33. doi: 10.1016/j.jaad.2003.11.066. PMID: 15097956. [PubMed: 15097956] [CrossRef]
69.
Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002 Sep;47(3):390–8. PMID: 12196749. [PubMed: 12196749]
70.
Haak CS, Togsverd-Bo K, Thaysen-Petersen D, et al. Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas--a randomized clinical trial. Br J Dermatol. 2015 Jan;172(1):215–22. doi: 10.1111/bjd.13166. PMID: 24903544. [PubMed: 24903544] [CrossRef]
71.
Hall VL, Leppard BJ, McGill J, et al. Treatment of basal-cell carcinoma: comparison of radiotherapy and cryotherapy. Clin Radiol. 1986 Jan;37(1):33–4. PMID: 3514075. [PubMed: 3514075]
72.
Ko DY, Kim KH, Song KH. A randomized trial comparing methyl aminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: results from a 12-month follow-up. Br J Dermatol. 2014 Jan;170(1):165–72. doi: 10.1111/bjd.12627. PMID: 24102369. [PubMed: 24102369] [CrossRef]
73.
Kuijpers DI, Thissen MR, Thissen CA, et al. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol. 2006 Jul–Aug;5(7):642–5. PMID: 16865869. [PubMed: 16865869]
74.
Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001 May;44(5):807–13. doi: 10.1067/mjd.2001.113689. PMID: 11312429. [PubMed: 11312429] [CrossRef]
75.
Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716–28. doi: 10.1016/s1470-2045(15)70100-2. PMID: 25981810. [PubMed: 25981810] [CrossRef]
76.
Miller BH, Shavin JS, Cognetta A, et al. Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel. J Am Acad Dermatol. 1997 Jan;36(1):72–7. PMID: 8996264. [PubMed: 8996264]
77.
Morton C, Horn M, Lehman J, et al. A 24-month update of a placebo controlled European study comparing MAL-PDT with cryotherapy and 5-fluoracil in patients with Bowen’s disease (Abstract P08.73) The 14th Congress of the European Academy of Dermatology and Venereology, London, UK. 12–15th October 2005. Journal of the European Academy of Dermatology and Venereology: JEADV; 2005. p. 237–8.
78.
Morton C, Horn M, Leman J, et al. A placebo controlled European study controlling methylaminolaevulinate photodynamic therapy with cryotherapy and 5-fluorocaril in patients with Bowen’s disease. Abstract P-33 The 85th BAD Annual Meeting 5–8th July 2005, Glasgow, UK. British journal of dermatology; 2005. p. 30.
79.
Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol. 2006 Jun;142(6):729–35. doi: 10.1001/archderm.142.6.729. PMID: 16785375. [PubMed: 16785375] [CrossRef]
80.
Morton CA, Whitehurst C, Moseley H, et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen’s disease. Br J Dermatol. 1996 Nov;135(5):766–71. PMID: 8977678. [PubMed: 8977678]
81.
Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol. 2008 Dec;9(12):1149–56. doi: 10.1016/s1470-2045(08)70260-2. PMID: 19010733. [PubMed: 19010733] [CrossRef]
82.
Orenberg EK, Miller BH, Greenway HT, et al. The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma. J Am Acad Dermatol. 1992 Nov;27(5 Pt 1):723–8. PMID: 1430394. [PubMed: 1430394]
83.
Patel GK, Goodwin R, Chawla M, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006 Jun;54(6):1025–32. doi: 10.1016/j.jaad.2006.01.055. PMID: 16713457. [PubMed: 16713457] [CrossRef]
84.
Petit JY, Avril MF, Margulis A, et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg. 2000 Jun;105(7):2544–51. PMID: 10845311. [PubMed: 10845311]
85.
Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004 Jan;140(1):17–23. doi: 10.1001/archderm.140.1.17. PMID: 14732655. [PubMed: 14732655] [CrossRef]
86.
Roozeboom MH, Aardoom MA, Nelemans PJ, et al. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. J Am Acad Dermatol. 2013 Aug;69(2):280–7. doi: 10.1016/j.jaad.2013.02.014. PMID: 23566914. [PubMed: 23566914] [CrossRef]
87.
Roozeboom MH, Arits AH, Mosterd K, et al. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial. J Invest Dermatol. 2016 Aug;136(8):1568–74. doi: 10.1016/j.jid.2016.03.043. PMID: 27113429. [PubMed: 27113429] [CrossRef]
88.
Roozeboom MH, Nelemans PJ, Mosterd K, et al. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial. Br J Dermatol. 2015 Mar;172(3):739–45. doi: 10.1111/bjd.13299. PMID: 25066012. [PubMed: 25066012] [CrossRef]
89.
Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br J Dermatol. 2003 Mar;148(3):539–43. PMID: 12653747. [PubMed: 12653747]
90.
Salmanpoor R, Motevalli D, Saki N, et al. Efficacy of excisional surgery, curettage and combined curettage and electrodessication in treatment of basal cell carcinoma. Iranian Journal of Dermatology. 2012;15(60):66–7. PMID: 2013120389.
91.
Schleier P, Berndt A, Kolossa S, et al. Comparison of aminolevulinic acid (ALA)-thermogel-PDT with methyl-ALA-thermogel-PDT in basal cell carcinoma. Photodiagnosis Photodyn Ther. 2007 Sep;4(3):197–201. doi: 10.1016/j.pdpdt.2007.04.004. PMID: 25047438. [PubMed: 25047438] [CrossRef]
92.
Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005 May;152(5):939–47. doi: 10.1111/j.1365-2133.2005.06486.x. PMID: 15888150. [PubMed: 15888150] [CrossRef]
93.
Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002 Sep;138(9):1165–71. PMID: 12224977. [PubMed: 12224977]
94.
Siller G, Rosen R, Freeman M, et al. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010 May;51(2):99–105. doi: 10.1111/j.1440-0960.2010.00626.x. PMID: 20546215. [PubMed: 20546215] [CrossRef]
95.
Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet. 2004 Nov 13–19;364(9447):1766–72. doi: 10.1016/s0140-6736(04)17399-6. PMID: 15541449. [PubMed: 15541449] [CrossRef]
96.
Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006 Jan;32(1):63–9. PMID: 16393600. [PubMed: 16393600]
97.
Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002 Dec;147(6):1227–36. PMID: 12452875. [PubMed: 12452875]
98.
Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol. 2008 Nov;22(11):1302–11. doi: 10.1111/j.1468-3083.2008.02803.x. PMID: 18624836. [PubMed: 18624836] [CrossRef]
99.
Thissen MR, Nieman FH, Ideler AH, et al. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg. 2000 Aug;26(8):759–64. PMID: 10940063. [PubMed: 10940063]
100.
Torres A, Niemeyer A, Berkes B, et al. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004 Dec;30(12 Pt 1):1462–9. doi: 10.1111/j.1524-4725.2004.30504.x. PMID: 15606733. [PubMed: 15606733] [CrossRef]
101.
Tran HT, Lee RA, Oganesyan G, et al. Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers Surg Med. 2012 Aug;44(6):459–67. doi: 10.1002/lsm.22032. PMID: 22511036. [PubMed: 22511036] [CrossRef]
102.
van der Geer S, Martens J, van Roij J, et al. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. Br J Dermatol. 2012 Jul;167(1):110–5. doi: 10.1111/j.1365-2133.2012.10924.x. PMID: 22385074. [PubMed: 22385074] [CrossRef]
103.
van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014 Nov;50(17):3011–20. doi: 10.1016/j.ejca.2014.08.018. PMID: 25262378. [PubMed: 25262378] [CrossRef]
104.
Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol. 2001 Apr;144(4):832–40. PMID: 11298545. [PubMed: 11298545]
105.
Wettstein R, Erba P, Itin P, et al. Treatment of basal cell carcinoma with surgical excision and perilesional interferon-alpha. J Plast Reconstr Aesthet Surg. 2013 Jul;66(7):912–6. doi: 10.1016/j.bjps.2013.03.008. PMID: 23566745. [PubMed: 23566745] [CrossRef]
106.
The use of laboratory animals. Notes for the guidance of research workers. Ann R Coll Surg Engl. 1973 Mar;52(3):193–7. PMID: 4700674. [PMC free article: PMC2388201] [PubMed: 4700674]
107.
Aguilar M, de Troya M, Martin L, et al. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen’s disease of the lower extremities. J Eur Acad Dermatol Venereol. 2010 Dec;24(12):1431–6. doi: 10.1111/j.1468-3083.2010.03664.x. PMID: 20456549. [PubMed: 20456549] [CrossRef]
108.
Ashby MA, Smith J, Ainslie J, et al. Treatment of nonmelanoma skin cancer at a large Australian center. Cancer. 1989 May 01;63(9):1863–71. PMID: 2702595. [PubMed: 2702595]
109.
Avila J, Bosch A, Aristizabal S, et al. Carcinoma of the pinna. Cancer. 1977 Dec;40(6):2891–5. PMID: 589557. [PubMed: 589557]
110.
Bean DJ, Rees RS, O’Leary JP, et al. Carcinoma of the hand: a 20-year experience. South Med J. 1984 Aug;77(8):998–1000. PMID: 6463702. [PubMed: 6463702]
111.
Cham BE, Daunter B, Evans RA. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Lett. 1991 Sep;59(3):183–92. PMID: 1913614. [PubMed: 1913614]
112.
Chernosky ME. Squamous cell and basal cell carcinomas: preliminary study of 3,817 primary skin cancers. South Med J. 1978 Jul;71(7):802–3, 6. PMID: 663726. [PubMed: 663726]
113.
Cox NH, Dyson P. Wound healing on the lower leg after radiotherapy or cryotherapy of Bowen’s disease and other malignant skin lesions. Br J Dermatol. 1995 Jul;133(1):60–5. PMID: 7669642. [PubMed: 7669642]
114.
Futoryan T, Grande D. Postoperative wound infection rates in dermatologic surgery. Dermatol Surg. 1995 Jun;21(6):509–14. PMID: 7773598. [PubMed: 7773598]
115.
Glass RL, Perez-Mesa CM. Management of inadequately excised epidermoid carcinoma. Arch Surg. 1974 Jan;108(1):50–1. PMID: 4808574. [PubMed: 4808574]
116.
Halnan KE, Britten MJ. Late functional and cosmetic results of treatment of eyelid tumours. Br J Ophthalmol. 1968 Jan;52(1):43–53. PMID: 5710508. [PMC free article: PMC506521] [PubMed: 5710508]
117.
Hansen JP, Drake AL, Walling HW. Bowen’s Disease: a four-year retrospective review of epidemiology and treatment at a university center. Dermatol Surg. 2008 Jul;34(7):878–83. doi: 10.1111/j.1524-4725.2008.34172.x. PMID: 18363722. [PubMed: 18363722] [CrossRef]
118.
Harrison PV. Therapy of basal cell carcinoma--treatment in 1980–81 compared with 1985–86 and advantages of shave excision for smaller tumours. Br J Dermatol. 1987 Sep;117(3):349–57. PMID: 3676083. [PubMed: 3676083]
119.
Honeycutt WM, Jansen GT. Treatment of squamous cell carcinoma of the skin. Arch Dermatol. 1973 Nov;108(5):670–2. PMID: 4750203. [PubMed: 4750203]
120.
Ibbotson SH, Valentine R, Hearn R. Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid? Photodermatol Photoimmunol Photomed. 2012 Oct;28(5):272–3. doi: 10.1111/j.1600-0781.2012.00684.x. PMID: 22971196. [PubMed: 22971196] [CrossRef]
121.
Jebodhsingh KN, Calafati J, Farrokhyar F, et al. Recurrence rates of basal cell carcinoma of the periocular skin: what to do with patients who have positive margins after resection. Can J Ophthalmol. 2012 Apr;47(2):181–4. doi: 10.1016/j.jcjo.2012.01.024. PMID: 22560426. [PubMed: 22560426] [CrossRef]
122.
Kadakia S, Ducic Y, Marra D, et al. Cutaneous squamous cell carcinoma of the scalp in the immunocompromised patient: review of 53 cases. Oral Maxillofac Surg. 2016 Jun;20(2):171–5. doi: 10.1007/s10006-016-0545-6. PMID: 26780196. [PubMed: 26780196] [CrossRef]
123.
Knox JM, Freeman RG, Duncan WC, et al. Treatment of skin cancer. South Med J. 1967 Mar;60(3):241–6. PMID: 6020491. [PubMed: 6020491]
124.
Kowalzick L, Rogozinski T, Schober C, et al. Treatment of basal cell carcinoma with intralesional recombinant interferon beta: A dose-finding study. European Journal of Dermatology. 1994;4(6):430–3. PMID: 1994253804.
125.
Marks R, Owens M, Walters SA. Efficacy and safely of 5% imiquimod cream in treating patients with multiple superficial basal cell carcinomas. Archives of Dermatology. 2004 October;140(10):1284–5. PMID: 2004440056. [PubMed: 15492200]
126.
Mazeron JJ, Chassagne D, Crook J, et al. Radiation therapy of carcinomas of the skin of nose and nasal vestibule: a report of 1676 cases by the Groupe Europeen de Curietherapie. Radiother Oncol. 1988 Nov;13(3):165–73. PMID: 3146781. [PubMed: 3146781]
127.
McIntosh GS, Osborne DR, Li AK, et al. Basal cell carcinoma--a review of treatment results with special reference to cryotherapy. Postgrad Med J. 1983 Nov;59(697):698–701. PMID: 6647186. [PMC free article: PMC2417682] [PubMed: 6647186]
128.
Mebed AH, Soliman HO, Gad ZS, et al. Multimodality treatment for non melanoma skin cancer: a prospective study done on 120 egyptian patients. J Egypt Natl Canc Inst. 2010 Mar;22(1):49–55. PMID: 21503006. [PubMed: 21503006]
129.
Nevrkla E, Newton KA. A survey of the treatment of 200 cases of basal cell carcinoma (1959–1966 inclusive). Br J Dermatol. 1974 Oct;91(4):429–33. PMID: 4425623. [PubMed: 4425623]
130.
Pereira CT, Kruger EA, Sayer G, et al. Mohs versus surgical excision in nonmelanoma skin cancers: does location matter? Ann Plast Surg. 2013 Apr;70(4):432–4. doi: 10.1097/SAP.0b013e3182834b47. PMID: 23486132. [PubMed: 23486132] [CrossRef]
131.
Rank B. Surgery and skin cancer. Ann R Coll Surg Engl. 1973 Mar;52(3):148–64. PMID: 4700671. [PMC free article: PMC2388202] [PubMed: 4700671]
132.
Reschly MJ, Shenefelt PD. Controversies in skin surgery: electrodessication and curettage versus excision for low-risk, small, well-differentiated squamous cell carcinomas. J Drugs Dermatol. 2010 Jul;9(7):773–6. PMID: 20677531. [PubMed: 20677531]
133.
Shiffman NJ. Squamous cell carcinomas of the skin of the pinna. Can J Surg. 1975 May;18(3):279–83. PMID: 1125865. [PubMed: 1125865]
134.
Tarstedt M, Gillstedt M, Wennberg Larko AM, et al. Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers. J Eur Acad Dermatol Venereol. 2016 Mar;30(3):420–3. doi: 10.1111/jdv.13558. PMID: 26841041. [PubMed: 26841041] [CrossRef]
135.
Tourli I, Langner D, Haroske G, et al. BASAL CELL CARCINOMA OF THE HEAD-AND-NECK REGION: A SINGLE CENTER ANALYSIS OF 1,750 TUMORS. Georgian Med News. 2016 Jan(250):33–9. PMID: 26870972. [PubMed: 26870972]
136.
Valentine RM, Ibbotson SH, Brown CT, et al. A quantitative comparison of 5-aminolaevulinic acid- and methyl aminolevulinate-induced fluorescence, photobleaching and pain during photodynamic therapy. Photochem Photobiol. 2011 Jan–Feb;87(1):242–9. doi: 10.1111/j.1751-1097.2010.00829.x. PMID: 21077899. [PubMed: 21077899] [CrossRef]
137.
Van Hezewijk M, Creutzberg CL, Putter H, et al. Efficacy of a hypofractionated schedule in electron beam radiotherapy for epithelial skin cancer: Analysis of 434 cases. Radiotherapy and Oncology. 2010 May;95(2):245–9. PMID: 2012354969. [PubMed: 20334941]
138.
Wang Y, Lin Y, Zhang HG, et al. A photodynamic therapy combined with topical 5-aminolevulinic acid and systemic hematoporphyrin derivative is more efficient but less phototoxic for cancer. Journal of Cancer Research and Clinical Oncology. 2016 01 Apr;142(4):813–21. PMID: 2015524013. [PubMed: 26581214]
139.
Werlinger KD, Upton G, Moore AY. Recurrence rates of primary nonmelanoma skin cancers treated by surgical excision compared to electrodesiccation-curettage in a private dermatological practice. Dermatol Surg. 2002 Dec;28(12):1138–42; discussion 42. PMID: 12472494. [PubMed: 12472494]
140.
Yoon M, Chougule P, Dufresne R, et al. Localized carcinoma of the external ear is an unrecognized aggressive disease with a high propensity for local regional recurrence. Am J Surg. 1992 Dec;164(6):574–7. PMID: 1463102. [PubMed: 1463102]
141.
Ahmed I, Berth-Jones J, Charles-Holmes S, et al. Comparison of cryotherapy with curettage in the treatment of Bowen’s disease: a prospective study. Br J Dermatol. 2000 Oct;143(4):759–66. PMID: 11069453. [PubMed: 11069453]
142.
Asgari MM, Bertenthal D, Sen S, et al. Patient satisfaction after treatment of nonmelanoma skin cancer. Dermatol Surg. 2009 Jul;35(7):1041–9. doi: 10.1111/j.1524-4725.2009.01181.x. PMID: 19438672. [PMC free article: PMC2710423] [PubMed: 19438672] [CrossRef]
143.
Ballester-Sanchez R, Pons-Llanas O, Candela-Juan C, et al. Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses. J Contemp Brachytherapy. 2016 Feb;8(1):48–55. doi: 10.5114/jcb.2016.57531. PMID: 26985197. [PMC free article: PMC4793064] [PubMed: 26985197] [CrossRef]
144.
Chren MM, Linos E, Torres JS, et al. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013 May;133(5):1188–96. doi: 10.1038/jid.2012.403. PMID: 23190903. [PMC free article: PMC3711403] [PubMed: 23190903] [CrossRef]
145.
Chren MM, Sahay AP, Bertenthal DS, et al. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007 Jun;127(6):1351–7. doi: 10.1038/sj.jid.5700740. PMID: 17301830. [PubMed: 17301830] [CrossRef]
146.
Chren MM, Sahay AP, Sands LP, et al. Variation in care for nonmelanoma skin cancer in a private practice and a veterans affairs clinic. Med Care. 2004 Oct;42(10):1019–26. PMID: 15377935. [PubMed: 15377935]
147.
Chren MM, Torres JS, Stuart SE, et al. Recurrence after treatment of nonmelanoma skin cancer: a prospective cohort study. Arch Dermatol. 2011 May;147(5):540–6. doi: 10.1001/archdermatol.2011.109. PMID: 21576572. [PMC free article: PMC3145327] [PubMed: 21576572] [CrossRef]
148.
Cosgarea R, Susan M, Crisan M, et al. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013 Aug;27(8):980–4. doi: 10.1111/j.1468-3083.2012.04619.x. PMID: 22738399. [PubMed: 22738399] [CrossRef]
149.
Graells J, Ojeda RM, Garcia-Cruz A. Effect of imiquimod as compared with surgery on the cancerization field in basal cell carcinoma. Actas Dermosifiliogr. 2014 Jan–Feb;105(1):53–9. doi: 10.1016/j.ad.2013.09.001. PMID: 24139468. [PubMed: 24139468] [CrossRef]
150.
Lippert J, Smucler R, Vlk M. Fractional carbon dioxide laser improves nodular basal cell carcinoma treatment with photodynamic therapy with methyl 5-aminolevulinate. Dermatol Surg. 2013 Aug;39(8):1202–8. doi: 10.1111/dsu.12242. PMID: 23725586. [PubMed: 23725586] [CrossRef]
151.
Pampena R, Palmieri T, Kyrgidis A, et al. Orthovoltage radiotherapy for nonmelanoma skin cancer (NMSC): Comparison between 2 different schedules. J Am Acad Dermatol. 2016 Feb;74(2):341–7. doi: 10.1016/j.jaad.2015.09.031. PMID: 26589877. [PubMed: 26589877] [CrossRef]
152.
Shah SM, Konnikov N, Duncan LM, et al. The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers Surg Med. 2009 Aug;41(6):417–22. doi: 10.1002/lsm.20787. PMID: 19588534. [PubMed: 19588534] [CrossRef]
153.
Sofen H, Gross KG, Goldberg LH, et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99–105.e1. doi: 10.1016/j.jaad.2015.03.013. PMID: 25913533. [PubMed: 25913533] [CrossRef]
154.
Sullivan TP, Dearaujo T, Vincek V, et al. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg. 2003 Dec;29(12):1181–6. PMID: 14725659. [PubMed: 14725659]
155.
Wilson LS, Pregenzer M, Basu R, et al. Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting. Dermatol Surg. 2012 Apr;38(4):570–84. doi: 10.1111/j.1524-4725.2011.02231.x. PMID: 22145798. [PMC free article: PMC3839857] [PubMed: 22145798] [CrossRef]
156.
Stuart SE, Schoen P, Jin C, et al. Tumor recurrence of keratinocyte carcinomas judged appropriate for Mohs micrographic surgery using Appropriate Use Criteria. J Am Acad Dermatol. 2017 Mar 29doi: 10.1016/j.jaad.2016.12.045. PMID: 28365039. [PMC free article: PMC5443650] [PubMed: 28365039] [CrossRef]
157.
Chren MM, Lasek RJ, Sahay AP, et al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001 Mar–Apr;5(2):105–10. doi: 10.1007/s102270000010. PMID: 11443481. [PubMed: 11443481] [CrossRef]
158.
Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996 Nov;107(5):707–13. PMID: 8875954. [PubMed: 8875954]
159.
Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012 Oct;67(4):531–50. doi: 10.1016/j.jaad.2012.06.009. PMID: 22959232. [PubMed: 22959232] [CrossRef]
160.
Chaimani A, Vasiliadis HS, Pandis N, et al. Effects of study precision and risk of bias in networks of interventions: a network meta-epidemiological study. Int J Epidemiol. 2013 Aug;42(4):1120–31. doi: 10.1093/ije/dyt074. PMID: 23811232. [PubMed: 23811232] [CrossRef]
161.
Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014;9(7):e99682. doi: 10.1371/journal.pone.0099682. PMID: 24992266. [PMC free article: PMC4084629] [PubMed: 24992266] [CrossRef]
162.
American Academy of Dermatology and AAD Association. Position Statement on Superficial Radiation Therapy for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinomas (SCC). 2014.
163.
American Academy of Dermatology and AAD Association. Position Statement on Electronic Surface Brachytherapy for Basal Cell Carcinoma (BCC) and Squamous Cell Carcinomas (SCC). 2016.
164.
Merola JF, Armstrong AW, Saraiya A, et al. International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. J Rheumatol. 2016 May;43(5):959–60. doi: 10.3899/jrheum.160114. PMID: 27134269. [PubMed: 27134269] [CrossRef]
165.
Chan AW, Fung K, Tran JM, et al. Application of Recursive Partitioning to Derive and Validate a Claims-Based Algorithm for Identifying Keratinocyte Carcinoma (Nonmelanoma Skin Cancer). JAMA Dermatol. 2016 Oct 01;152(10):1122–7. doi: 10.1001/jamadermatol.2016.2609. PMID: 27533718. [PubMed: 27533718] [CrossRef]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (7.6M)

Other titles in these collections

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...